HOWLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Werewolf Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$1.04+0.06 (+6.12%)
Close on Oct 19, 2026
- Market cap
- $50.54M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 39.5% | -123.9% | |
| Return on assets | – | – | -62.0% | |
| Current ratio | – | 17.58 | 1.62 | |
| Debt to equity | – | – | 0.00 | |
| Interest coverage | – | – | -11.5× | |
| Diluted shares | – | 1M | 47M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Werewolf Therapeutics generated $232.56M from operations and spent $5.13M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$232.56M
Used
$5.13M
Capital expenditure$5.13M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$60.82M
- Cash generatingOperating cash flow above zero-$60.29M
- Return on assets improvedROA up on the prior year-40.3% → -47.9%
- Earnings backed by cashOperating cash flow above net income-$60.29M vs -$60.82M
- Less leverageLong-term debt to assets fell20.6% → 0.0%
- Better liquidityCurrent ratio rose7.45 → 1.62
- No dilutionShare count did not rise44M → 47M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –